These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1425 related articles for article (PubMed ID: 25092278)

  • 1. Prognostic value of quantitative contrast-enhanced cardiovascular magnetic resonance for the evaluation of sudden death risk in patients with hypertrophic cardiomyopathy.
    Chan RH; Maron BJ; Olivotto I; Pencina MJ; Assenza GE; Haas T; Lesser JR; Gruner C; Crean AM; Rakowski H; Udelson JE; Rowin E; Lombardi M; Cecchi F; Tomberli B; Spirito P; Formisano F; Biagini E; Rapezzi C; De Cecco CN; Autore C; Cook EF; Hong SN; Gibson CM; Manning WJ; Appelbaum E; Maron MS
    Circulation; 2014 Aug; 130(6):484-95. PubMed ID: 25092278
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characteristics and clinical significance of late gadolinium enhancement by contrast-enhanced magnetic resonance imaging in patients with hypertrophic cardiomyopathy.
    Rubinshtein R; Glockner JF; Ommen SR; Araoz PA; Ackerman MJ; Sorajja P; Bos JM; Tajik AJ; Valeti US; Nishimura RA; Gersh BJ
    Circ Heart Fail; 2010 Jan; 3(1):51-8. PubMed ID: 19850699
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Myocardial fibrosis severity on cardiac magnetic resonance imaging predicts sustained arrhythmic events in hypertrophic cardiomyopathy.
    Prinz C; Schwarz M; Ilic I; Laser KT; Lehmann R; Prinz EM; Bitter T; Vogt J; van Buuren F; Bogunovic N; Horstkotte D; Faber L
    Can J Cardiol; 2013 Mar; 29(3):358-63. PubMed ID: 22749647
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic value of late gadolinium enhancement in clinical outcomes for hypertrophic cardiomyopathy.
    Green JJ; Berger JS; Kramer CM; Salerno M
    JACC Cardiovasc Imaging; 2012 Apr; 5(4):370-7. PubMed ID: 22498326
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cardiovascular magnetic resonance characteristics in children with hypertrophic cardiomyopathy.
    Chaowu Y; Shihua Z; Jian L; Li L; Wei F
    Circ Heart Fail; 2013 Sep; 6(5):1013-20. PubMed ID: 23873474
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Late gadolinium enhancement is common in patients with hypertrophic cardiomyopathy and no clinical risk factors for sudden cardiac death: A single center experience.
    Lyons KS; Dixon LJ; Johnston N; Noad R; Hamilton A; McKeag N; Horan P
    Cardiol J; 2014; 21(1):29-32. PubMed ID: 23990187
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The value of cardiac magnetic resonance and distribution of late gadolinium enhancement for risk stratification of sudden cardiac death in patients with hypertrophic cardiomyopathy.
    Klopotowski M; Kukula K; Malek LA; Spiewak M; Polanska-Skrzypczyk M; Jamiolkowski J; Dabrowski M; Baranowski R; Klisiewicz A; Kusmierczyk M; Jasinska A; Jarmus E; Kruk M; Ruzyllo W; Witkowski A; Chojnowska L
    J Cardiol; 2016 Jul; 68(1):49-56. PubMed ID: 26363820
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic significance of late gadolinium enhancement on cardiac magnetic resonance in patients with hypertrophic cardiomyopathy.
    He D; Ye M; Zhang L; Jiang B
    Heart Lung; 2018; 47(2):122-126. PubMed ID: 29174363
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ESC sudden-death risk model in hypertrophic cardiomyopathy: Incremental value of quantitative contrast-enhanced CMR in intermediate-risk patients.
    Hinojar R; Zamorano JL; Gonzalez Gómez A; Plaza Martin M; Esteban A; Rincón LM; Portugal JC; Jimenez Nácher JJ; Fernández-Golfín C
    Clin Cardiol; 2017 Oct; 40(10):853-860. PubMed ID: 28614597
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Myocardial fibrosis on cardiac magnetic resonance and cardiac outcomes in hypertrophic cardiomyopathy: a meta-analysis.
    Briasoulis A; Mallikethi-Reddy S; Palla M; Alesh I; Afonso L
    Heart; 2015 Sep; 101(17):1406-11. PubMed ID: 26060120
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic Value of LGE-CMR in HCM: A Meta-Analysis.
    Weng Z; Yao J; Chan RH; He J; Yang X; Zhou Y; He Y
    JACC Cardiovasc Imaging; 2016 Dec; 9(12):1392-1402. PubMed ID: 27450876
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic Role of Late Gadolinium Enhancement in Patients With Hypertrophic Cardiomyopathy and Low-to-Intermediate Sudden Cardiac Death Risk Score.
    Todiere G; Nugara C; Gentile G; Negri F; Bianco F; Falletta C; Novo G; Di Bella G; De Caterina R; Zachara E; Re F; Clemenza F; Sinagra G; Emdin M; Aquaro GD
    Am J Cardiol; 2019 Oct; 124(8):1286-1292. PubMed ID: 31447011
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cardiac magnetic resonance imaging findings predict major adverse events in apical hypertrophic cardiomyopathy.
    Hanneman K; Crean AM; Williams L; Moshonov H; James S; Jiménez-Juan L; Gruner C; Sparrow P; Rakowski H; Nguyen ET
    J Thorac Imaging; 2014 Nov; 29(6):331-9. PubMed ID: 25314027
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The amount of late gadolinium enhancement outperforms current guideline-recommended criteria in the identification of patients with hypertrophic cardiomyopathy at risk of sudden cardiac death.
    Freitas P; Ferreira AM; Arteaga-Fernández E; de Oliveira Antunes M; Mesquita J; Abecasis J; Marques H; Saraiva C; Matos DN; Rodrigues R; Cardim N; Mady C; Rochitte CE
    J Cardiovasc Magn Reson; 2019 Aug; 21(1):50. PubMed ID: 31412875
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phenotypic expression in hypertrophic cardiomyopathy and late gadolinium enhancement on cardiac magnetic resonance.
    Caetano F; Botelho A; Trigo J; Silva J; Almeida I; Venâncio M; Pais J; Sanches C; Leitão Marques A
    Rev Port Cardiol; 2014 May; 33(5):261-7. PubMed ID: 24909443
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic significance of late gadolinium enhancement quantification in cardiac magnetic resonance imaging of hypertrophic cardiomyopathy with systolic dysfunction.
    Funada A; Kanzaki H; Noguchi T; Morita Y; Sugano Y; Ohara T; Hasegawa T; Hashimura H; Ishibashi-Ueda H; Kitakaze M; Yasuda S; Ogawa H; Anzai T
    Heart Vessels; 2016 May; 31(5):758-70. PubMed ID: 25820658
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Variables associated with contrast-enhanced cardiovascular magnetic resonance in hypertrophic cardiomyopathy: clinical implications.
    Payá E; Marín F; González J; Gimeno JR; Feliu E; Romero A; Ruiz-Espejo F; Roldán V; Climent V; de la Morena G; Valdés M
    J Card Fail; 2008 Jun; 14(5):414-9. PubMed ID: 18514934
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term risk of sudden cardiac death in hypertrophic cardiomyopathy: a cardiac magnetic resonance outcome study.
    Greulich S; Seitz A; Herter D; Günther F; Probst S; Bekeredjian R; Gawaz M; Sechtem U; Mahrholdt H
    Eur Heart J Cardiovasc Imaging; 2021 Jun; 22(7):732-741. PubMed ID: 33458753
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of the presence and amount of myocardial fibrosis by cardiac magnetic resonance on arrhythmic outcome and sudden cardiac death in nonischemic dilated cardiomyopathy.
    Perazzolo Marra M; De Lazzari M; Zorzi A; Migliore F; Zilio F; Calore C; Vettor G; Tona F; Tarantini G; Cacciavillani L; Corbetti F; Giorgi B; Miotto D; Thiene G; Basso C; Iliceto S; Corrado D
    Heart Rhythm; 2014 May; 11(5):856-63. PubMed ID: 24440822
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of unrecognized myocardial scar detected by cardiac magnetic resonance imaging on event-free survival in patients presenting with signs or symptoms of coronary artery disease.
    Kwong RY; Chan AK; Brown KA; Chan CW; Reynolds HG; Tsang S; Davis RB
    Circulation; 2006 Jun; 113(23):2733-43. PubMed ID: 16754804
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 72.